BYAH revenueFY2025$2.52M
- FY YoY
- +6.0%
BYAH revenue was $2.52M for fiscal 2025 (ended Oct 31, 2025), up 6.0% from fiscal 2024. It rose in 2 of the last 3 fiscal years.
Park Ha Biological Technology Co. Ltd. (BYAH) financials
For fiscal 2025 (ended Oct 31, 2025), Park Ha Biological Technology Co. Ltd. reported $2.52M of revenue and -$24.36M of net income.
- Revenue, FY2025
- $2.52M
- Revenue growth, YoY
- +6.0%
- Net income, FY2025
- -$24.36M
- Net margin
- -965.0%
- Free cash flow, FY2025
- -$3.0K
- EPS, diluted, FY2025
- -$41.38
- Cash
- $3.79M
- P/S
- 2.96
- Market cap
- $7.5M
FY2022FY2025
FY2022FY2025
FY2022FY2025
BYAH revenue and earnings growth
BYAH net incomeFY2025-$24.36M
BYAH net income was -$24.36M for fiscal 2025 (ended Oct 31, 2025), compared with $478.6K in fiscal 2024.
BYAH EPSFY2025-$41.38
BYAH diluted EPS was -$41.38 for fiscal 2025 (ended Oct 31, 2025), compared with $0.96 in fiscal 2024.
BYAH free cash flowFY2025-$3.0K
BYAH free cash flow was -$3.0K for fiscal 2025 (ended Oct 31, 2025), compared with $874.9K in fiscal 2024.
Income statement
| Line item | Oct 31, 2025 | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 |
|---|---|---|---|---|
| Revenue | $2.52M | $2.38M | $2.46M | $1.92M |
| Cost of revenue | $142.5K | $195.3K | $311.0K | $509.2K |
| Gross profit | $2.38M | $2.19M | $2.15M | $1.41M |
| Research and development | $238.2K | $36.7K | $30.9K | $60.7K |
| Selling, general and admin | $25.48M | $814.9K | $485.0K | $707.5K |
| Operating income | -$24.15M | $793.7K | $1.18M | $197.0K |
| Interest expense | $41 | - | - | $194 |
| Pre-tax income | -$24.08M | $793.4K | $1.18M | $190.0K |
| Income tax | $280.6K | $314.9K | $329.5K | -$1.3K |
| Net income | -$24.36M | $478.6K | $852.0K | $191.3K |
| EPS, basic | -$41.38 | $0.96 | $1.70 | $0.01 |
| EPS, diluted | -$41.38 | $0.96 | $1.70 | $0.01 |
| Diluted shares | 588,866 | 500,000 | 500,000 | 25.0M |
Balance sheet
| Line item | Oct 31, 2025 | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $3.79M | $547.5K | $1.03M | $574.7K |
| Receivables | $255.8K | $330.9K | $361.7K | - |
| Inventory | $75.2K | $71.5K | $95.9K | - |
| Current assets | $5.50M | $2.84M | $2.18M | - |
| Total assets | $5.95M | $3.08M | $2.26M | - |
| Current liabilities | $1.88M | $1.52M | $1.24M | - |
| Total liabilities | $1.96M | $1.58M | $1.25M | - |
| Shareholders' equity | $3.99M | $1.51M | $1.01M | $150.3K |
Cash flow
| Line item | Oct 31, 2025 | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | $85.9K | $960.5K | $126.5K | $1.44M |
| Capital expenditures | $88.8K | $85.6K | $22.7K | $11.9K |
| Free cash flow | -$3.0K | $874.9K | $103.9K | $1.43M |
| Investing cash flow | -$572.9K | -$508.1K | $1.02M | -$1.55M |
| Financing cash flow | $3.74M | -$957.4K | -$676.9K | $669.7K |
| Stock-based compensation | $24.07M | - | - | - |
| Depreciation and amortization | $109.4K | $22.7K | $20.1K | $30.5K |
Key ratios
| Line item | Oct 31, 2025 | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 |
|---|---|---|---|---|
| Revenue growth, YoY | 6.0% | -3.1% | 28.1% | - |
| Net income growth, YoY | - | -43.8% | 345.4% | - |
| EPS growth, YoY | - | -43.5% | - | - |
| Gross margin | 94.4% | 91.8% | 87.4% | 73.5% |
| Operating margin | -956.5% | 33.3% | 48.0% | 10.3% |
| Net margin | -965.0% | 20.1% | 34.6% | 10.0% |
| Free cash flow margin | -0.1% | 36.7% | 4.2% | 74.5% |
| Return on equity | -609.9% | 31.8% | 84.2% | 127.3% |
| Return on assets | -409.3% | 15.5% | 37.6% | - |
| Current ratio | 2.92 | 1.87 | 1.75 | - |
Source: XBRL data Park Ha Biological Technology Co. Ltd. files with the SEC, latest filing dated May 15, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
BYAH peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BYAH | $2.52M | +6.0% | -$24.36M | -965.0% | $7.5M |
| PG | $87.92B | +3.5% | $16.03B | 18.2% | $390.13B |
| UL | €50.50B | -3.8% | €9.47B | 18.7% | $143.50B |
| ECL | $17.37B | +9.3% | $2.08B | 12.0% | $86.03B |
| CL | $21.28B | +5.9% | $2.05B | 9.6% | $77.85B |
| EL | $15.28B | +5.8% | $368.00M | 2.4% | $41.00B |
| HLN | £11.03B | -1.8% | £1.67B | 15.1% | $39.43B |
| KVUE | $15.53B | +3.5% | $1.69B | 10.9% | $37.57B |
| CHD | $6.25B | +1.7% | $774.80M | 12.4% | $26.27B |
BYAH FAQ
9 questionsWhat is BYAH revenue?
Park Ha Biological Technology Co. Ltd. (BYAH) reported $2.52M of revenue for fiscal 2025 (ended Oct 31, 2025). That is up 6.0% from the year before.Is BYAH profitable?
No. Park Ha Biological Technology Co. Ltd. reported a net loss of $24.36M for fiscal 2025 (ended Oct 31, 2025).How much cash and debt does BYAH have?
Park Ha Biological Technology Co. Ltd. reported $3.79M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is BYAH revenue growing?
Park Ha Biological Technology Co. Ltd.'s revenue changed +6.0% in fiscal 2025, to $2.52M.What is BYAH gross margin?
Park Ha Biological Technology Co. Ltd.'s gross profit was $2.38M on $2.52M of revenue for fiscal 2025 (ended Oct 31, 2025), a gross margin of 94.4%.What is BYAH free cash flow?
Park Ha Biological Technology Co. Ltd. generated -$3.0K of free cash flow for fiscal 2025 (ended Oct 31, 2025), which is operating cash flow of $85.9K less capital expenditures.What is BYAH earnings per share?
Diluted earnings per share were -$41.38 for fiscal 2025 (ended Oct 31, 2025), from SEC filings, restated for any stock split those filings show.When did BYAH last report financial results?
The latest statements here come from Park Ha Biological Technology Co. Ltd.'s 20-F/A filed on May 15, 2026, covering the period ended Oct 31, 2025.Where does this BYAH financial data come from?
Quantisnow builds these statements from the structured XBRL data Park Ha Biological Technology Co. Ltd. files with the SEC. It is provided for information only and is not investment advice.